Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: xl-820, vatalanib, rivoceranib mesylate +72 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 5,503 | 0.76 |
| pathways Reactome | 7 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 8892
Sealed predictions
- KDR in dopamine neurons, braak+0.22 (p 0.565) → -0.15 (p 0.699)receipt 8899
Swarm cases
receipt 8899: KDR in dopamine neurons, braak
- power
- full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.493, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 7; without severely affected donors -0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KDR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts